The END Fund
The END Fund is a 501(c)(3) collaborative philanthropy organization managing four programmatic funds that pool philanthropic capital and pharmaceutical drug donations to support mass drug administration, surgeries, and health worker training against six neglected tropical diseases across 31 countries.
- Company typePrivate
- Founded2012
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingServices
What The END Fund does
The END Fund is a 501(c)(3) collaborative philanthropy organization founded in 2012 and headquartered in New York, with additional hubs in London and Nairobi. The organization manages a portfolio of four programmatic funds — the Flagship Fund, Deworming Innovation Fund (launched 2020), Reaching the Last Mile Fund (launched 2017), and ARISE Fund — dedicated to controlling and eliminating six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis) that collectively affect approximately 1.4 billion people globally.
The Fund's operating model is to pool philanthropic capital from 25+ anchor investors (including the Bill & Melinda Gates Foundation, Legatum Foundation, Reaching the Last Mile/UAE Presidential Court, Children's Investment Fund Foundation, Helmsley Charitable Trust, Mackenzie Scott, and UK Aid) and coordinate drug donations from MSD, GSK, Pfizer, Merck KGaA, and Johnson & Johnson. These resources are channeled through a network of over 50 programmatic partners (Amref Health Africa, Helen Keller Intl, FHI 360, Sightsavers, The Carter Center, RTI International) and government health ministries in 31 countries across Africa, the Middle East, South Asia, and South America to deliver mass drug administration campaigns, surgeries, and health worker training.
The Fund has delivered 2.4 billion treatments cumulatively since 2012, including 240 million people treated in 2025 alone, and reports $4.48 billion in cumulative treatment value, 238,784 surgeries performed, and 8.33 million health workers trained. Revenue mechanics rely on multi-year anchor commitments with annual billing cadence rather than transactional giving. The Fund is not a technology company but operates an Interactive Data Visualization Tool and uses precision mapping for disease targeting. As a 501(c)(3) nonprofit, it has no equity ownership structure and is not backed by venture capital or private equity investors.
The END Fund firmographics
Firmographics- Name
- The END Fund
- Legal name
- The END Fund Inc.
- Website
- https://endfund.org
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- The END Fund is a 501(c)(3) collaborative philanthropy organization managing four programmatic funds that pool philanthropic capital and pharmaceutical drug donations to support mass drug administration, surgeries, and health worker training against six neglected tropical diseases across 31 countries.
- Ownership category
- akta.pro rank
The END Fund industry classification
Industry- Product category
- Global Health Philanthropy
- NAICS
- Grantmaking Foundations (813211), Grantmaking and Giving Services (8132), Grantmaking and Giving Services (81321), Voluntary Health Organizations (813212)
- SIC
- Services-Social Services (8300)
- akta.pro primary industry
- Public Charities & Grantmaking Intermediaries (BPAGAKAE)
- akta.pro secondary industries
- Global Health Financing Mechanisms & Pooled Funds (HLAJAOAC), Global Health Financing Mechanisms (HLAJAKAC), Public Health Financing, Budgeting & Grants Management (HLAJAMAC), Community Health & Prevention Program Funding (HLAJALAF), Chronic Disease & Health Promotion Program Funding (HLAJALAJ), Healthcare Access & Life Sciences Impact Funds (FSANAJAI)
Keywords
Where The END Fund is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
The END Fund business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Philanthropic Donations and Grants: The END Fund raises resources from a community of dedicated philanthropic investors and donors. The organization mobilizes private capital to support country-led NTD programs. Donors include foundations, family philanthropists, corporations, and government aid agencies. The fund model enables pooling of resources to maximize impact.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | $1M+ Anchor Investors |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
The END Fund product offering
Product offeringCore offering
The END Fund is a collaborative philanthropy fund that pools private capital and donated pharmaceuticals to finance country-led mass drug administration campaigns, surgeries, and health worker training targeting six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis). It works through a network of 50+ NGO implementation partners and government health ministries across 31 countries to deliver treatments at scale.
Product overview
The END Fund is a collaborative philanthropy organization managing a portfolio of four programmatic funds dedicated to eliminating six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis). The core products are the Flagship Fund (cornerstone fund for mass drug administration), Deworming Innovation Fund (innovative deworming techniques in 4 countries), Reaching the Last Mile Fund (elimination of river blindness and lymphatic filariasis in Africa), and ARISE Fund (government co-financing and capacity building in 5 countries). The organization also offers an Interactive Data Tool for visualizing NTD burden and treatment data. The funds work by pooling private capital and partnering with governments, pharmaceutical companies, and programmatic partners to deliver treatments, perform surgeries, and train health workers.
Differentiator
Problem solved
Functional benefit
Brands
- Flagship Fund: The END Fund's cornerstone fund working to treat and prevent five neglected tropical diseases through mass drug administration campaigns, surgeries, and health worker training.
- Deworming Innovation Fund
- Reaching the Last Mile Fund
- ARISE Fund
Products and services
- Flagship Fund The END Fund's cornerstone fund that works to treat and prevent five neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, and trachoma) through mass drug administration campaigns, surgeries, health worker training, and prevention education. Available for philanthropic investment by foundations, family offices, corporates, and government aid agencies.
- Deworming Innovation Fund A fund that pilots innovative techniques to stop the spread of schistosomiasis and intestinal worms through precision mapping, expanded treatment to adults, nutrition programming, and WASH programs in Ethiopia, Kenya, Rwanda, and Zimbabwe. Designed for philanthropic investors seeking innovative approaches to parasitic worm elimination.
- Reaching the Last Mile Fund A multi-donor initiative established by the UAE Presidential Court and the Bill & Melinda Gates Foundation to eliminate river blindness and lymphatic filariasis across 39 African countries. Open to multi-donor philanthropic investment for continent-wide disease elimination.
- ARISE Fund
Quantifiable outcome
- 240 million people treated in 2025
- +6 more outcomes
Companies that use The END Fund
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
The END Fund technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
The END Fund partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core/anchor, core and supporting.
- World Health Organization (WHO)core/anchorKEY: WHO provides technical guidance, guidelines for NTD elimination, and verification of elimination status. The END Fund aligns its programs with WHO's NTD Roadmap 2021-2030.
- Amref Health Africacore/anchorMajor programmatic partner operating in multiple countries. Supports END Fund programs including visceral leishmaniasis treatment in East Africa, trachoma elimination in Ethiopia, and intestinal worm/schistosomiasis mapping in Kenya.
- Helen Keller IntlcoreProgrammatic partner supporting NTD treatment and prevention programs globally.
- FHI 360coreProgrammatic partner providing technical expertise and implementation support for NTD programs.
- SightsaverscoreProgrammatic partner focused on eliminating trachoma and other NTDs, particularly in West Africa.
- The Carter CentercoreProgrammatic partner with long history in NTD control, particularly river blindness elimination efforts.
- RTI InternationalcoreProgrammatic partner providing technical and implementation support for NTD programs.
- CBMsupportingProgrammatic partner supporting disability-inclusive development and NTD programs.
- Liverpool School of Tropical MedicinesupportingAcademic partner providing research and technical expertise in NTD control and elimination.
- MITOSATHsupportingProgrammatic partner operating in Nigeria, supporting deworming and schistosomiasis treatment programs.
- Africa CDCsupportingIn June 2025, Africa CDC partnered with END Fund and WHO to establish a digital portal for NTD planning and data sharing across 50 African countries.
- International Trachoma Initiative (ITI)coreCoordinates delivery of azithromycin donated by Pfizer through the Zithromax shipment tracker for trachoma elimination.
Scale indicators10 records
Recent moves11 records
Expansion highlights6 records
The END Fund competitors and assessment
Company assessmentBroad incumbents
- Clinton Health Access Initiative (CHAI): Global health organization that works with governments and partners to strengthen health systems and improve access to medicines in low- and middle-income countries. Comparable as a large-scale philanthropic intermediary driving NTD and related disease programs across Africa and Asia.
- Global Fund to Fight AIDS, Tuberculosis and Malaria: Large-scale global health financing partnership pooling government and private resources to combat three major infectious diseases. Directly comparable as a multi-donor pooled fund model delivering treatments through country-led programs with WHO alignment.
- Gavi, the Vaccine Alliance: Global pooled fund that mobilizes public and private capital to deliver vaccines at scale to lower-income countries. Comparable as a public-private pooled financing mechanism that aggregates donor capital and partners with pharma and governments for last-mile health delivery.
- Wellcome Trust: Large UK-based charitable foundation funding global health research and infectious disease programs including NTDs. Comparable as a major global health philanthropic funder operating at a similar scale to END Fund's anchor investors.
Direct peers
- Helen Keller International: Global health NGO working on NTD treatment, vision, and nutrition programs in low-income countries. Listed as a core programmatic partner of END Fund and shares the same target populations and country footprint.
- The Carter Center: Humanitarian organization founded by former US President Jimmy Carter with major river blindness and trachoma elimination programs across Africa and the Americas. Listed as a programmatic partner of END Fund and operates a directly comparable disease elimination model.
- International Trachoma Initiative (ITI): Dedicated program coordinating Pfizer's Zithromax donations for trachoma elimination across 40+ countries. Listed as a core programmatic partner of END Fund and operates a directly comparable single-disease pooled-distribution model.
- Sightsavers: International NGO that prevents avoidable blindness and advocates for disability rights, with significant NTD programming in trachoma and river blindness across Africa and Asia. A direct programmatic partner of END Fund and one of its closest operating peers.
- Drugs for Neglected Diseases initiative (DNDi): Collaborative, patient-needs driven R&D organization developing new treatments for neglected diseases including leishmaniasis and helminth infections. Comparable as a global health pooled-fund-style organization focused on NTDs but oriented to drug development rather than delivery.
- Children's Investment Fund Foundation (CIFF): Major philanthropic foundation that supports NTD deworming and elimination programs globally, including as a major anchor investor in END Fund. Comparable as a large, strategic philanthropy funding the same deworming and NTD elimination outcomes.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
The END Fund social profiles
Digital presenceThe END Fund financial estimates
Financial estimateRevenue estimate
Valuation estimate
The END Fund leadership team
Management profileNumber of profiles
Profiles8 records
The END Fund subsidiaries and ownership
Company hierarchySubsidiaries4 records
The END Fund funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The END Fund M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The END Fund
What does The END Fund do?
The END Fund is a collaborative philanthropy fund that pools private capital and donated pharmaceuticals to finance country-led mass drug administration campaigns, surgeries, and health worker training targeting six neglected tropical diseases (intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis). It works through a network of 50+ NGO implementation partners and government health ministries across 31 countries to deliver treatments at scale.
Is The END Fund a public or private company?
The END Fund is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was The END Fund founded?
The END Fund was founded in 2012. It employs 51 to 100 people.
Where is The END Fund based?
The END Fund is headquartered in New York, United States, in the North America region.
How does The END Fund make money?
One revenue line is on record: philanthropic Donations and Grants.
Who are The END Fund's main competitors?
Broad incumbents on record are Clinton Health Access Initiative (CHAI), Global Fund to Fight AIDS, Tuberculosis and Malaria, Gavi, the Vaccine Alliance and Wellcome Trust. Direct peers are Helen Keller International, The Carter Center, International Trachoma Initiative (ITI), Sightsavers, Drugs for Neglected Diseases initiative (DNDi) and Children's Investment Fund Foundation (CIFF).
Does The END Fund have an API?
No public API is recorded for The END Fund.
What industry is The END Fund in?
The END Fund's product category is Global Health Philanthropy. Its primary akta.pro industry code is BPAGAKAE, Public Charities & Grantmaking Intermediaries, with a secondary code of HLAJAOAC, Global Health Financing Mechanisms & Pooled Funds. Its NAICS code is 813211 and its SIC code is 8300.